Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2282512A
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK2282512A is GSK's egg-derived, inactivated split-virion quadrivalent seasonal influenza vaccine. It contains hemagglutinin antigens from two influenza A subtypes and two influenza B lineages and induces strain-specific humoral immunity for active prevention of seasonal influenza. It was studied in children and adults and marketed in different territories under the brands AlphaRix Tetra, Fluarix Quadrivalent, Fluarix Tetra, and Influsplit Tetra. ([gsk-studyregister.com](https://www.gsk-studyregister.com/trials/116926))
- Brand names
- AlphaRix TetraFluarix QuadrivalentFluarix TetraInflusplit Tetra
- Other names
- FLU-Q-QIV
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on GSK2282512A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2282512A.